Candriam S.C.A. Acquires 71,752 Shares of Cardinal Health, Inc. $CAH

Key Points

• Candriam S.C.A. increased its Cardinal Health stake by 287.6%, buying 71,752 shares to hold 96,698 shares worth about $21.6 million at quarter-end.
• Cardinal Health beat quarterly estimates, reporting adjusted EPS of $3.26 and revenue of $67.51 billion, and raised its fiscal 2027 adjusted EPS outlook to $12.80–$13.00.
• Company insiders sold 210,271 shares worth about $49.6 million over three months. Analysts remain broadly positive, with a “Moderate Buy” consensus and an average price target of $272.50.

Candriam S.C.A. lifted its holdings in Cardinal Health, Inc. (NYSE:CAH - Free Report) by 287.6% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 96,698 shares of the company's stock after purchasing an additional 71,752 shares during the period. Candriam S.C.A.'s holdings in Cardinal Health were worth $21,594,000 at the end of the most recent quarter.

Other hedge funds have also recently modified their holdings of the company. Downshift Financial LLC lifted its holdings in Cardinal Health by 3,666.7% during the third quarter. Downshift Financial LLC now owns 113 shares of the company's stock worth $25,000 after buying an additional 110 shares during the period. Investors Research Corp purchased a new position in shares of Cardinal Health in the 2nd quarter valued at $29,000. Maryland Capital Advisors Inc. increased its holdings in shares of Cardinal Health by 12,600.0% in the 3rd quarter. Maryland Capital Advisors Inc. now owns 127 shares of the company's stock valued at $28,000 after acquiring an additional 126 shares during the period. Allied Private Wealth LLC purchased a new position in shares of Cardinal Health in the 2nd quarter valued at $30,000. Finally, NBH Bank purchased a new position in shares of Cardinal Health in the 2nd quarter valued at $31,000. Hedge funds and other institutional investors own 87.17% of the company's stock.

Insider Transactions at Cardinal Health

In related news, CAO Mary C. Scherer sold 2,302 shares of the company's stock in a transaction dated Wednesday, August 19th. The stock was sold at an average price of $237.39, for a total transaction of $546,471.78. Following the transaction, the chief accounting officer directly owned 2,811 shares of the company's stock, valued at $667,303.29. This represents a 45.02% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CEO Jason M. Hollar sold 44,529 shares of the stock in a transaction dated Wednesday, August 19th. The shares were sold at an average price of $236.18, for a total value of $10,516,859.22. Following the completion of the sale, the chief executive officer owned 190,603 shares of the company's stock, valued at approximately $45,016,616.54. This trade represents a 18.94% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 210,271 shares of company stock worth $49,626,657. 0.12% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

Several research analysts have recently commented on the company. Barclays boosted their price target on Cardinal Health from $258.00 to $275.00 and gave the stock an "overweight" rating in a research report on Thursday, August 13th. Wells Fargo & Company raised their price objective on Cardinal Health from $245.00 to $277.00 and gave the company an "overweight" rating in a research report on Wednesday, August 12th. Leerink Partners set a $292.00 target price on Cardinal Health in a research note on Tuesday, August 11th. JPMorgan Chase & Co. boosted their target price on shares of Cardinal Health from $215.00 to $260.00 and gave the stock a "neutral" rating in a report on Thursday, August 13th. Finally, Morgan Stanley boosted their target price on shares of Cardinal Health from $265.00 to $286.00 and gave the stock an "overweight" rating in a report on Friday, October 30th. Sixteen research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $272.50.

Cardinal Health Stock Down 0.3%

Shares of CAH opened at $270.99 on Monday. The company has a market cap of $62.75 billion, a price-to-earnings ratio of 35.06, a price-to-earnings-growth ratio of 1.59 and a beta of 0.53. Cardinal Health, Inc. has a twelve month low of $180.45 and a twelve month high of $286.29. The company has a 50 day moving average of $240.45 and a two-hundred day moving average of $223.55.

Cardinal Health (NYSE:CAH - Get Free Report) last released its quarterly earnings results on Thursday, November 5th. The company reported $3.26 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.94 by $0.32. The business had revenue of $67.51 billion for the quarter, compared to analyst estimates of $66.67 billion. Cardinal Health had a net margin of 0.71% and a negative return on equity of 102.72%. The business's revenue for the quarter was up 5.5% on a year-over-year basis. During the same period in the previous year, the company earned $2.55 earnings per share. On average, sell-side analysts expect that Cardinal Health, Inc. will post 12.86 EPS for the current year.

Cardinal Health News Summary

Here are the key news stories impacting Cardinal Health this week:

• Positive Sentiment: Fiscal Q1 adjusted EPS was $3.26, ahead of analyst expectations, while revenue rose 5% year over year to $67.5 billion and also topped estimates. The company raised its FY2027 adjusted EPS guidance to $12.80–$13.00, above the FactSet estimate of $12.57. Cardinal Health reports first-quarter results and raises outlook
• Positive Sentiment: Management cited specialty growth, strong demand for generics and customer renewals as supports for the raised outlook. Cardinal Health also completed a $500 million share repurchase program during the quarter. Q1 earnings call highlights
• Positive Sentiment: Royal Bank of Canada raised its price target to $295 from $276 and reiterated an “outperform” rating, signaling continued analyst optimism. Royal Bank of Canada recommendations
• Negative Sentiment: Medical distribution faced pressure, including modest commodity and petroleum-related headwinds. The company’s results and raised forecast indicate these pressures were outweighed by strength in pharmaceuticals and specialty. Cardinal Health sees healthy demand despite commodity pressure

Cardinal Health Company Profile

Cardinal Health is a healthcare services and products company that distributes pharmaceuticals and medical supplies. Its customers include pharmacies, hospitals, surgery centers, physician offices and other healthcare providers.

The company's businesses include pharmaceutical distribution and specialty services, as well as the sourcing and distribution of medical and surgical products. Its offerings support areas such as specialty medications, medication management and supply-chain operations.

Cardinal Health traces its roots to a wholesale business founded in Ohio in 1971 and later expanded into pharmaceutical distribution.

Want to see what other hedge funds are holding CAH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cardinal Health, Inc. (NYSE:CAH - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.